Saturday 17 October 2026
Export PBM’s income statement to Excel — free account
Psyence Biomedical Ltd.
In the quarter to September 2025, EPS was flat and free cash flow fell 707.2%, each against the same quarter a year earlier.
4.22
0.10
−2.31%
Follow PBM
| Sep '25 | Mar '25 | Sep '24 | Mar '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
8.09 | 11.04 | 0.64 | 0.09 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.78 | 0.00 | 1.70 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | — | 0.00 | 0.00 | |
Capex/Depreciation |
(0.08) | — | (3.56) | (28.50) | |
Interest Coverage |
(537.96) | — | (312.73) | — | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow per Share |
0.00 | — | 0.00 | 0.00 | |
Cash per Share |
30.37 | 0.00 | 350.38 | 0.00 | |
Shareholders Equity per Share |
50.07 | 0.00 | (224.12) | 0.00 | |
Interest Debt per Share |
0.00 | — | 0.00 | — | |
Book value per Share |
50.07 | 0.00 | (224.12) | 0.00 | |
Free Cash Flow |
(2.03) | — | (1.52) | (2.95) | |
Working Capital |
6.69 | 5.97 | (1.27) | (10.98) | |
Capital Expenditures |
0.00 | — | (0.01) | (0.01) | |
Net Current Asset Value |
6.69 | 5.97 | (1.27) | (10.98) | |
| Other line items | |||||
Quick Ratio |
7.82 | 10.61 | 0.59 | 0.07 | |
Revenue per Share |
0.00 | — | 0.00 | — | |
Operating CF per Share |
0.00 | — | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Average Receivables |
0.11 | 0.10 | 0.09 | 0.44 | |
Average Assets |
14.61 | 133.12 | 129.37 | 129.47 | |
Average Common Equity |
4.19 | 4.09 | 0.13 | 116.84 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates